DR. NOEL LAUDI M.D. NPI 1235221110

NPI Details

DR. Noel Laudi, M.D. is a medical oncology internal medicine in Coon Rapids, MN with 34 years of experience. The provider is an internist who specializes in the diagnosis and treatment of all types of cancer and other benign and malignant tumors. This specialist decides on and administers therapy for these malignancies as well as consults with surgeons and radiotherapists on other treatments for cancer. DR. Noel Laudi, M.D. NPI is 1235221110. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

The provider's business location address is:

11850 BLACKFOOT ST NW STE 300
COON RAPIDS, MN
ZIP 55433-772
Phone: (763) 236-0808
Fax: (763) 236-6065

The NPI 1235221110 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, docetaxel, 1 mg (HCPCS:J9171)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Injection, atropine sulfate, 0.01 mg (HCPCS:J0461)
• Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
• Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg (HCPCS:Q5118)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, irinotecan, 20 mg (HCPCS:J9206)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Blood creatinine level (HCPCS:82565)
• Measurement of immunoglobulin light chains (HCPCS:83521)
• Ferritin (blood protein) level (HCPCS:82728)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Blood potassium level (HCPCS:84132)
• Blood chloride level (HCPCS:82435)
• Urea nitrogen level to assess kidney function, quantitative (HCPCS:84520)
• Blood sodium level (HCPCS:84295)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Blood glucose (sugar) level (HCPCS:82947)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Protein measurement, serum (HCPCS:84165)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Red blood cell sedimentation rate, to detect inflammation, non-automated (HCPCS:85651)
• Magnesium level (HCPCS:83735)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Initial hospital inpatient care per day, typically 50 minutes (HCPCS:99222)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Liver function blood test panel (HCPCS:80076)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Thyroxine (thyroid chemical), free (HCPCS:84439)
• Red blood count automated, with additional calculations (HCPCS:85046)
• Immunologic analysis technique on serum (immunofixation) (HCPCS:86334)
• Urinalysis, manual test (HCPCS:81002)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Administration of chemotherapy into vein using push technique (HCPCS:96409)
• Unclassified drugs (HCPCS:J3490)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Calcium level, total (HCPCS:82310)
• Application of on-body injector for under skin injection (HCPCS:96377)
• Follow-up hospital inpatient care per day, typically 15 minutes (HCPCS:99231)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Advance care planning, first 30 minutes (HCPCS:99497)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)

The enumeration date for this NPI number is 9/29/2006 and was last updated on 5/31/2023.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.